{"id":1,"date":"2025-05-28T14:56:45","date_gmt":"2025-05-28T06:56:45","guid":{"rendered":"http:\/\/us01.suyinetwork.com:8082\/?p=1"},"modified":"2025-09-19T11:47:49","modified_gmt":"2025-09-19T03:47:49","slug":"asco-2025","status":"publish","type":"post","link":"https:\/\/oncology.dualityinfo.cn\/index.php\/2025\/05\/28\/asco-2025\/","title":{"rendered":"ASCO 2025"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"580\" height=\"72\" src=\"https:\/\/oncology.dualityinfo.cn\/wp-content\/uploads\/2025\/05\/asco-logo-1.png\" alt=\"asco logo\" class=\"wp-image-25\" srcset=\"https:\/\/oncology.dualityinfo.cn\/wp-content\/uploads\/2025\/05\/asco-logo-1.png 580w, https:\/\/oncology.dualityinfo.cn\/wp-content\/uploads\/2025\/05\/asco-logo-1-300x37.png 300w\" sizes=\"auto, (max-width: 580px) 100vw, 580px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DB-1310, a HER3-targeted ADC, in patients with advanced solid tumors: Preliminary results from the Phase 1\/2a trial<\/strong><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file alignwide has-border-color\" style=\"border-color:#000000;border-width:1px;border-radius:0px\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/oncology.dualityinfo.cn\/wp-content\/uploads\/2025\/05\/Lisberg_ASCO2025_DB-1310-.pdf\" type=\"application\/pdf\" style=\"width:100%;height:720px\" aria-label=\"Embed of Lisberg_ASCO2025_DB-1310.\"><\/object><a id=\"wp-block-file--media-7cecfb4d-a8a9-40c6-bffe-b382a2d93303\" href=\"https:\/\/oncology.dualityinfo.cn\/wp-content\/uploads\/2025\/05\/Lisberg_ASCO2025_DB-1310-.pdf\">Lisberg_ASCO2025_DB-1310<\/a><a href=\"https:\/\/oncology.dualityinfo.cn\/wp-content\/uploads\/2025\/05\/Lisberg_ASCO2025_DB-1310-.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7cecfb4d-a8a9-40c6-bffe-b382a2d93303\">Download<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DB-1310, a HER3-targeted ADC, in patients with advanced solid tumors: Preliminary results from the Phase 1\/2a trial<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/posts\/1","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/comments?post=1"}],"version-history":[{"count":10,"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/posts\/1\/revisions"}],"predecessor-version":[{"id":55,"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/posts\/1\/revisions\/55"}],"wp:attachment":[{"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/media?parent=1"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/categories?post=1"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncology.dualityinfo.cn\/index.php\/wp-json\/wp\/v2\/tags?post=1"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}